The purpose of this study is to investigate pancreatic cancer liver metastasis. This study investigates the effects of a combination of an investigational medication and chemotherapy drugs.
Researchers are evaluating the safety and effectiveness of this treatment combination. The study focuses on understanding how well these treatments work together and their safety profile.
- Who can participate: Adults aged 18 to 75 years with pancreatic cancer liver metastases who have not received prior systemic treatment may participate. Participants should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and normal organ function.
- Study details: Participants will receive an investigational medication along with chemotherapy drugs. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.